{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":5,"youtube":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05909397\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"VERITAC-3","nct_id":"NCT05909397","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=veritac-3-nct05909397. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"VERITAC-3","arms":[{"description":"Participants will receive:\n\n* Vepdegestrant, orally, once daily, continuously, in a 28-day cycle, plus\n* Palbociclib, orally, once daily for 21 consecutive days followed by 7 days off treatment in a 28 day cycle","label":"Arm A (Investigational Arm)","type":"EXPERIMENTAL"},{"description":"Participants will receive:\n\n* Letrozole, orally, once daily, continuously, in a 28-day cycle, plus\n* Palbociclib, orally, once daily for 21 consecutive days followed by 7 days off treatment, in a 28-day cycle.","label":"Arm B (Comparator Arm):","type":"ACTIVE_COMPARATOR"}],"collaborators":["Arvinas Estrogen Receptor, Inc."],"completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":59,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Vepdegestrant (ARV-471/PF-07850327)","type":"DRUG"},{"name":"Palbociclib","type":"COMBINATION_PRODUCT"},{"name":"Letrozole","type":"DRUG"},{"name":"Palbociclib","type":"COMBINATION_PRODUCT"}],"last_update":"2026-02-10","lead_sponsor":"Pfizer","official_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF VEPDEGESTRANT (ARV-471/PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Study Lead-in (SLI): Incidence of Grade 4 neutropenia","timeFrame":"From randomization date up to Cycle 4 (each cycle is 28 days)."},{"measure":"SLI: Incidence of dose reduction","timeFrame":"From randomization date up to Cycle 4 (each cycle is 28 days)."},{"measure":"SLI: Incidence of drug discontinuation.","timeFrame":"From randomization date up to Cycle 4 (each cycle is 28 days)."},{"measure":"Phase 3: Progression-Free Survival","timeFrame":"From randomization date, every 12 weeks, to date of first documentation of progression or death, up to approximately 4 years."}],"references":[],"start_date":{"date":"2023-08-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05909397"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/veritac-3-nct05909397"}